Jieling Miao

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Eve T. Rodler, Priyanka Sharma, William E. Barlow et al. · The Lancet Oncology · 2023 · 92 citations · Full text

Breast Oncology, Medicine, Pharmacology +6

Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)

Kevin Kalinsky, William E. Barlow, Funda Meric‐Bernstam et al. · Cancer Research · 2021 · 88 citations

Breast Oncology, Cancer Management, Gynecology +18

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline <i>BRCA</i>-associated breast cancer (SWOG S1416).

Priyanka Sharma, Eve T. Rodler, William E. Barlow et al. · Journal of Clinical Oncology · 2020 · 49 citations

Tumor Biology, Brca1 Methylation, Breast Oncology +15

Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)

Darya Kizub, Jieling Miao, Mark M. Schubert et al. · Supportive Care in Cancer · 2020 · 37 citations · Full text

Bone Disease, Breast Oncology, Oncology +9

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Taofeek K. Owonikoko, Mary W. Redman, Lauren A. Byers et al. · Clinical Lung Cancer · 2021 · 30 citations · Full text

Lung-map Substudy S1400g, Medicine, Pathology +7